These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 15258309)
1. The role of CD94/NKG2 in innate and adaptive immunity. Gunturi A; Berg RE; Forman J Immunol Res; 2004; 30(1):29-34. PubMed ID: 15258309 [TBL] [Abstract][Full Text] [Related]
2. Preferential survival of CD8 T and NK cells expressing high levels of CD94. Gunturi A; Berg RE; Forman J J Immunol; 2003 Feb; 170(4):1737-45. PubMed ID: 12574337 [TBL] [Abstract][Full Text] [Related]
3. The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene. Cantoni C; Biassoni R; Pende D; Sivori S; Accame L; Pareti L; Semenzato G; Moretta L; Moretta A; Bottino C Eur J Immunol; 1998 Jan; 28(1):327-38. PubMed ID: 9485212 [TBL] [Abstract][Full Text] [Related]
4. Direct binding of purified HLA class I antigens by soluble NKG2/CD94 C-type lectins from natural killer cells. Ding Y; Sumitran S; Holgersson J Scand J Immunol; 1999 May; 49(5):459-65. PubMed ID: 10320637 [TBL] [Abstract][Full Text] [Related]
5. Expression of Ly49E and CD94/NKG2 on fetal and adult NK cells. Van Beneden K; Stevenaert F; De Creus A; Debacker V; De Boever J; Plum J; Leclercq G J Immunol; 2001 Apr; 166(7):4302-11. PubMed ID: 11254682 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487 [TBL] [Abstract][Full Text] [Related]
7. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. Valés-Gómez M; Reyburn HT; Erskine RA; López-Botet M; Strominger JL EMBO J; 1999 Aug; 18(15):4250-60. PubMed ID: 10428963 [TBL] [Abstract][Full Text] [Related]
8. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes. Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501 [TBL] [Abstract][Full Text] [Related]
9. Triggering of effector functions on a CD8+ T cell clone upon the aggregation of an activatory CD94/kp39 heterodimer. Bellón T; Heredia AB; Llano M; Minguela A; Rodriguez A; López-Botet M; Aparicio P J Immunol; 1999 Apr; 162(7):3996-4002. PubMed ID: 10201920 [TBL] [Abstract][Full Text] [Related]
10. CD94/NKG2 expression does not inhibit cytotoxic function of lymphocytic choriomeningitis virus-specific CD8+ T cells. Miller JD; Peters M; Oran AE; Beresford GW; Harrington L; Boss JM; Altman JD J Immunol; 2002 Jul; 169(2):693-701. PubMed ID: 12097371 [TBL] [Abstract][Full Text] [Related]
11. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Mingari MC; Ponte M; Bertone S; Schiavetti F; Vitale C; Bellomo R; Moretta A; Moretta L Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1172-7. PubMed ID: 9448304 [TBL] [Abstract][Full Text] [Related]
12. Expression of inhibitory receptors Ly49E and CD94/NKG2 on fetal thymic and adult epidermal TCR V gamma 3 lymphocytes. Van Beneden K; De Creus A; Stevenaert F; Debacker V; Plum J; Leclercq G J Immunol; 2002 Apr; 168(7):3295-302. PubMed ID: 11907085 [TBL] [Abstract][Full Text] [Related]
13. Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes. Arlettaz L; Villard J; de Rham C; Degermann S; Chapuis B; Huard B; Roosnek E Eur J Immunol; 2004 Dec; 34(12):3456-64. PubMed ID: 15517612 [TBL] [Abstract][Full Text] [Related]
14. Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells. Kusumi M; Yamashita T; Fujii T; Nagamatsu T; Kozuma S; Taketani Y J Reprod Immunol; 2006 Jun; 70(1-2):33-42. PubMed ID: 16488482 [TBL] [Abstract][Full Text] [Related]
15. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Gumá M; Busch LK; Salazar-Fontana LI; Bellosillo B; Morte C; García P; López-Botet M Eur J Immunol; 2005 Jul; 35(7):2071-80. PubMed ID: 15940674 [TBL] [Abstract][Full Text] [Related]
16. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Llano M; Lee N; Navarro F; García P; Albar JP; Geraghty DE; López-Botet M Eur J Immunol; 1998 Sep; 28(9):2854-63. PubMed ID: 9754572 [TBL] [Abstract][Full Text] [Related]
17. Orderly and nonstochastic acquisition of CD94/NKG2 receptors by developing NK cells derived from embryonic stem cells in vitro. Lian RH; Maeda M; Lohwasser S; Delcommenne M; Nakano T; Vance RE; Raulet DH; Takei F J Immunol; 2002 May; 168(10):4980-7. PubMed ID: 11994449 [TBL] [Abstract][Full Text] [Related]
18. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295 [TBL] [Abstract][Full Text] [Related]
19. Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity. Jensen PE; Sullivan BA; Reed-Loisel LM; Weber DA Immunol Res; 2004; 29(1-3):81-92. PubMed ID: 15181272 [TBL] [Abstract][Full Text] [Related]
20. CD69-triggered ERK activation and functions are negatively regulated by CD94 / NKG2-A inhibitory receptor. Zingoni A; Palmieri G; Morrone S; Carretero M; Lopez-Botel M; Piccoli M; Frati L; Santoni A Eur J Immunol; 2000 Feb; 30(2):644-51. PubMed ID: 10671222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]